Mersana has developed highly differentiated and innovative antibody-drug conjugate (ADC) platforms, with both cytotoxic and immunostimulatory payloads, that allow for customization and optimization of ADCs for a given target and indication.

Mersana’s innovative platforms have enabled us to build a pipeline for both Mersana and our collaborators. Our ADCs in preclinical studies and clinical trials are first-in-class molecules that target multiple tumor types with high unmet medical need.

Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options.

Jan 10, 2025 · CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on

Questions regarding this Policy statement should be sent to [email protected]. Information regarding Mersana’s clinical trials, as well as clinical trials and expanded access programs for other potential therapies, can be found on www.clinicaltrials.gov.

The development of ADCs is not a one-size-fits-all approach. In fact, a number of diverse factors impact the properties of an ADC, including payload, drug-to-antibody ratio, site of conjugation and homogeneity. For each target antigen, there is an optimal combination of these factors. Our novel and highly differentiated platforms allow us to optimize these properties for […]

Immunosynthen, Mersana’s proprietary STING agonist platform, generates systemically administered ADCs that locally activate STING signaling in both tumor-resident immune cells and in antigen expressing cells, unlocking the anti-tumor potential of innate immune stimulation.

At Mersana, we all share a singular vision: to create a world where all patients triumph over cancer. We know that the actions of each one of us matter, and that our success depends on our ability to work together.

Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer.

Molecular Cancer Therapeutics, a Journal of the American Association for Cancer Research (AACR) June, 2023 UPGRADE-A: Phase 1 Expansion Trial of the NaPi2b-Directed Antibody Drug Conjugate Upifitamab Rilsodotin in Combination With Carboplatin in Patients With High-Grade Serous Ovarian Cancer